Terumo (TRUMY)
(Delayed Data from OTC)
$18.81 USD
-0.34 (-1.78%)
Updated Oct 3, 2024 03:59 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
TRUMY 18.81 -0.34(-1.78%)
Will TRUMY be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TRUMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TRUMY
Here's Why Momentum in Terumo (TRUMY) Should Keep going
Are You Looking for a Top Momentum Pick? Why Terumo Corp. (TRUMY) is a Great Choice
TRUMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Terumo (TRUMY) a New Buy Stock
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Other News for TRUMY
MicroVention Rebrands to Terumo Neuro ? Reflects Expanded Focus and Strategic Growth
Terumo Corporation (TRUMF) Q1 2025 Earnings Call Transcript
Terumo Establishes Corporate Venture Capital "Terumo Ventures"
Terumo Gaining Share In Growth Markets, But Consistency Still A Question
MicroVention Announces Release of CLinical EValuation of WEB? 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms